IL-LANIFICIO
5.6.2024 09:01:33 CEST | Business Wire | Press release
Il Lanificio, the premium Italian apparel brand, is pleased to announce that it is opening two new stores in Pescara, Italy and Aubonne, Switzerland. These new openings will increase Il Lanificio’s total portfolio to 18 stores across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605960836/en/
The Pescara store will open on 7 June, with the Swiss store due to open in July, marking Il Lanificio’s third international outlet, joining existing locations in San Marino and Mendrisio, Switzerland and emphasising the brand's growing European presence.
Il Lanificio is a premium Italian apparel brand for men and women, known for its high-quality fabrics, exceptional tailoring and its commitment to deliver specialist, Italian craftsmanship direct to customers. The brand blends tradition with contemporary style, offering collections that cater to all demographics across outlets and online retail platforms. The new stores will be versatile, light and authentic, designed to embrace the customer with a warm welcome and communicate the quality and authenticity of its products. A new, multi-language e-commerce platform completes the customer omnichannel experience.
Since being acquired in 2018 by Njord Partners, Il Lanificio has benefitted from a renewed focus on its outlet business and an ambitious growth plan. Last year the Company grew its number of stores by 60% and its revenues by 40%. Il Lanificio intends to open up to 10 further stores in Europe by the end of 2025.
Filippo Vadda, CEO of Il Lanificio, commented: “Il Lanificio is internationally recognized as a high-quality apparel brand and the opening of these new stores underlines our commitment to growth both in Italy and internationally. We have doubled our number of outlets since 2021 and are excited to continue this expansion across Europe as we target the opening of six new stores this year, showcasing the best of our made-in-Italy offerings”.
Arvid Trolle, Partner at Njord Partners, said: “We are very pleased to see Il Lanificio go from strength to strength as an influential and growing apparel brand. Njord recognized the heritage and potential of the Il Lanificio brand and we are delighted that our investment in the business has ensured the sustainability and growth of the business. The company's performance and expansion are testament to the hard work and dedication of Il Lanificio’s team and we are excited by the promising future that lies ahead for us all.”
About Il Lanificio
Il Lanificio is an Italian outlet apparel brand of luxury made-in-Italy products. It is recognised by customers for having one of the best price-to-quality offers in the casual-chic and formal market. The first Il Lanificio retail store opened in 2002, and now has 15 stores across Italy, two in Switzerland and one in San Marino. Il Lanificio continues to grow whilst remaining focused on traditional design and excellent quality.
To find out more visit: https://www.illanificio.it/en/
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations, its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605960836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom